SCHEMBL4735702

SCHEMBL4735702

COc1ccc(-c2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)c2c(N)onc12

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 18/20 0.78
FLT3 P36888 16/20 0.78
KIT P10721 13/20 0.78
FLT1 P17948 12/20 0.78
CSF1R P07333 10/20 0.78
PDGFRB P09619 4/20 0.78
TEK Q02763 3/20 0.78
FLT4 P35916 9/20 0.58
LCK P06239 8/20 0.58
LYN P07948 8/20 0.58
BLK P51451 8/20 0.58
RPS6KB1 P23443 7/20 0.58
NTRK2 Q16620 7/20 0.58
AURKB Q96GD4 7/20 0.58
FYN P06241 6/20 0.58
ROCK2 O75116 6/20 0.58
RET P07949 6/20 0.58
NTRK1 P04629 6/20 0.58
RPS6KA3 P51812 6/20 0.58
MAP4K2 Q12851 6/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4736487 0.92 KDR (0.65) KDRFLT3KITFLT1CSF1R
SCHEMBL5249636 0.91 KDR (0.67) KDRFLT3KITFLT1CSF1R
SCHEMBL5249943 0.90 KDR (0.70) KDRFLT3KITFLT1CSF1R
SCHEMBL4735873 0.88 KDR (0.64) KDRFLT3KITFLT1CSF1R
SCHEMBL425740 0.88 KDR (1.00) KDRFLT3KITFLT1CSF1R
SCHEMBL4739162 0.87 KDR (0.66) KDRFLT3KITFLT1CSF1R
SCHEMBL4738551 0.87 KDR (0.66) KDRFLT3KITFLT1CSF1R
SCHEMBL4735281 0.87 KDR (0.65) KDRFLT3KITFLT1CSF1R
SCHEMBL1383935 0.87 KDR (0.62) KDRFLT3KITFLT1CSF1R
SCHEMBL1379843 0.86 KDR (0.77) KDRFLT3KITFLT1CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008080110-A1 METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR ALCON, INC. (CH) 2008-07-03 WO claimed
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP claimed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO claimed
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP disclosed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO disclosed